Novartis transforms its Global Health & Corporate Responsibility organization.
Jul 08, 2019
Novartis has transformed its Global Health & Corporate Responsibility (GH&CR) organization. The change consolidates and streamlines expertise and resources to achieve a stronger focus on the areas where the company can have the greatest impact.
“This transformation is yet another demonstration of our unwavering commitment to place global health and corporate responsibility at the core of our business strategy,” said Patrice Matchaba, Group Head, Global Health & Corporate Responsibility.
The new GH&CR organization will oversee end-to-end execution of the company’s global health priorities, from discovery through development to implementation.
Our flagship global health priorities
The new organization brings together the company’s flagship global health priorities. Read more about our key achievements.
To date, we have donated more than 60 million multidrug therapies, reaching more than 7 million patients to eliminate leprosy.
Novartis Foundation sharpens its focus on digital, data and AI
The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health. This new mandate builds on 40 years of striving for sustainable impact on health in low-income populations, most recently by focusing on leprosy elimination and cardiovascular health, in addition to digital health.
Novartis Foundation to focus fully on how digital, data and AI can transform global health.